Pharmathene Inc Q4 2010 Earnings Conference Call Transcript - Thomson StreetEvents

Pharmathene Inc Q4 2010 Earnings Conference Call Transcript

Pharmathene Inc Q4 2010 Earnings Conference Call Transcript - Thomson StreetEvents
Pharmathene Inc Q4 2010 Earnings Conference Call Transcript
Published Mar 28, 2011
9 pages (4799 words) — Published Mar 28, 2011
Price US$ 54.00  |  Buy this Report Now

About This Report

  
Abstract:

Edited Transcript of ALT.OQ earnings conference call or presentation 28-Mar-11 8:30pm GMT

  
Brief Excerpt:

...Operator Good day, ladies and gentlemen, and welcome to the Fourth Quarter 2010 PharmAthene, Incorporated Earnings Conference Call. My name is Melanie and I will your coordinator today. At this time, all participants are in a listen-only mode. We will accept your questions at the end of this conference. (Operator Instructions) As a reminder, today's call is being recorded. I would now like to turn the call over to Stacey Jurchison, Director of Corporate Communications. Please proceed. Stacey Jurchison ...

  
Report Type:

Transcript

Source:
Thomson StreetEvents
Company:
Altimmune Inc
Ticker
ALT.OQ
Time
8:30pm GMT
Format:
PDF Adobe Acrobat
Buy Now

The following is excerpted from the question-and-answer section of the transcript.

(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)

Question: Joe Pantginis - ROTH Capital Partners - Analyst : Hi, guys. Thanks for taking the question, and good afternoon. A couple of quick questions on SparVax. First, thanks, Tom, for the update on all the analytical things you guys have been doing for the tech transfer. Can you fast-forward a little bit and maybe discuss a little of the capacity that you'll have once you have the 100-liter scale in place and the timing that might go along with this capacity to deliver doses for the Strategic National Stockpile as well as for any potential ex-US interest on the drug?

Question: Joe Pantginis - ROTH Capital Partners - Analyst : Okay.

Question: Joe Pantginis - ROTH Capital Partners - Analyst : Super. And maybe just a quick follow-up on that. After you submit the second White Paper after you complete the tech transfer, based on the guidance you received from BARDA, what kind of potential timelines would you then be looking at for another potential funding announcement?

Question: Joe Pantginis - ROTH Capital Partners - Analyst : Sure. Thanks a lot, guys.

Question: Joe Pantginis - ROTH Capital Partners - Analyst : Great. Thanks again.

Question: Matt Duffy - BDR Research - Analyst : Good afternoon, and thanks for taking my question. I have a couple of things. I wonder if we could go a little further on the BAA request? How far do you think that will take you in development in terms of both timing and milestones?

Question: Matt Duffy - BDR Research - Analyst : I meant for SparVax, yes. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.

Question: Matt Duffy - BDR Research - Analyst : Okay, great. And then, as you're just looking at some of the financials, do you have a number for cash burn that you're thinking about for 2011? And what's your fully diluted share count at this point?

Question: Matt Duffy - BDR Research - Analyst : Okay, great. Thanks very much.

Question: Nathan Cali - Noble Financial - Analyst : Hey, guys. Good afternoon. Thanks for taking the questions. Just a quick question on the summary judgment brief that the judge will make an opinion on in April. What are the expectations there? Is he going to make any comments publicly? Will there be any information out on that? And what do you guys kind of expect from that?

Question: Nathan Cali - Noble Financial - Analyst : Okay. Thank you.

Table Of Contents

Altimmune Inc Q4 2020 Earnings Call Transcript – 2021-02-25 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 25-Feb-21 1:30pm GMT

Altimmune Inc Q3 2020 Earnings Call Transcript – 2020-11-10 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 10-Nov-20 1:30pm GMT

Altimmune Inc Annual Shareholders Meeting Transcript – 2020-09-24 – US$ 54.00 – Edited Transcript of ALT.OQ shareholder or annual meeting 24-Sep-20 2:00pm GMT

Altimmune Inc Q2 2020 Earnings Call Transcript – 2020-08-12 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 12-Aug-20 12:30pm GMT

PharmAthene, Inc. Conference Call to Discuss Delaware Court of Chancery Decision Transcript – 2011-09-23 – US$ 54.00 – Edited Transcript of ALT.OQ conference call or presentation 23-Sep-11 1:00pm GMT

PharmAthene, Inc. Q3 2010 Earnings Conference Call Transcript – 2010-11-11 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 11-Nov-10 9:30pm GMT

PharmAthene, Inc. Q2 2010 Earnings Conference Call Transcript – 2010-08-12 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 12-Aug-10 8:30pm GMT

Pharmathene Q1 2010 Earnings Conference Call Transcript – 2010-05-11 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 11-May-10 8:30pm GMT

Pharmathene Q4 2009 Earnings Conference Call Transcript – 2010-03-23 – US$ 54.00 – Edited Transcript of ALT.OQ earnings conference call or presentation 23-Mar-10 8:30pm GMT

Pharmathene Conference Call to provide an update on its rPA program Transcript – 2009-12-09 – US$ 54.00 – Edited Transcript of ALT.OQ conference call or presentation 9-Dec-09 2:00pm GMT

More from Thomson StreetEvents

Thomson StreetEvents—Thomson StreetEvents is a leading provider of Web-based solutions for the investment community, offering services that transform the way companies communicate and meet disclosure requirements while assisting investors in managing and leveraging this information. Thomson StreetEvents service offers institutional investors a one-stop solution for managing corporate disclosure information by aggregating conference calls, webcasts, transcripts, call summaries, and other financial information into a time-saving, efficiency tool.
Purchase Thomson StreetEvents' Transcripts (verbatim reports) and Briefs (call summaries) of earnings, guidance, M&A and other corporate calls directly through Alacra. Discounted prices apply to reports produced over two weeks ago.

About the Author


Cite this Report

  
MLA:
Thomson StreetEvents. "Pharmathene Inc Q4 2010 Earnings Conference Call Transcript" Mar 28, 2011. Alacra Store. Nov 06, 2026. <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2010-Pharmathene-Inc-Earnings-Conference-Call-T3901930>
  
APA:
Thomson StreetEvents. (2011). Pharmathene Inc Q4 2010 Earnings Conference Call Transcript Mar 28, 2011. New York, NY: Alacra Store. Retrieved Nov 06, 2026 from <http://www.alacrastore.com/thomson-streetevents-transcripts/Q4-2010-Pharmathene-Inc-Earnings-Conference-Call-T3901930>
  
US$ 54.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Credit Research from one place.